Product Pipeline

Xenon is focused on advancing our ion channel neurology pipeline.

Our pipeline includes four distinct therapeutic candidates – XEN496, XEN1101, XEN901, and XEN007 – that are aimed at treating neurological disorders, including epilepsy. We intend to pursue a variety of development strategies, such as those focused on using a “precision medicine” approach to address rare pediatric disorders, including KCNQ2 epilepsy, as well as those targeting broader patient populations, such as adult patients with focal epilepsy.

* A physician-led, Phase 2 proof-of-concept study is ongoing to examine XEN007 as an adjunctive treatment in pediatric patients diagnosed with treatment-resistant childhood absence epilepsy (CAE).

Medical Affairs

Learn more about our ongoing clinical trials

View Medical Affairs

See publications related to our clinical development candidates

View Publications

Find out more about collaborating with Xenon

View Partners